Institution
University of Lorraine
Education•Nancy, France•
About: University of Lorraine is a education organization based out in Nancy, France. It is known for research contribution in the topics: Population & Context (language use). The organization has 11942 authors who have published 25010 publications receiving 425227 citations. The organization is also known as: Lorraine University.
Papers published on a yearly basis
Papers
More filters
TL;DR: In this paper, annealing of the α+α′ microstructure is performed and the resulting microstructural evolution is analyzed, along with its impact on the tensile properties.
117 citations
TL;DR: Recent clinical trials in patients with heart failure with preserved ejection fraction (HFpEF) have provided important insights into participant selection strategies and appraise trial patient selection methodologies in relation to outcomes.
117 citations
TL;DR: The efficacy and safety of new and emerging biological agents that are currently investigated in IBD clinical trials are reviewed.
Abstract: Biological agents for inflammatory bowel diseases (IBD) targeting tumor necrosis factor (TNF) have changed the way to treat IBD refractory to standard medications and allowed us to reach new therapeutic goals such as mucosal healing and deep remission. A better understanding of the components of the pathological processes that are a hallmark of IBD has led to the development of a new family of biological agents in Crohn’s disease and ulcerative colitis. Biosimilars, which are copy versions of currently licensed biological agents, will be soon available. The biosimilar of infliximab is as effective and as safe as its originator in rheumatologic conditions, while a new anti-TNF agent, namely golimumab, has been recently approved for refractory ulcerative colitis. Beyond TNF blockers, anti-adhesion molecules appear to be a potent drug class for IBD. Vedolizumab was recently approved for both Crohn’s disease and ulcerative colitis. Numerous other compounds are in the pipeline. Ustekinumab looks very promising for Crohn’s disease. Smad7 antisense oligonucleotide might enrich our armamentarium if preliminary data are confirmed in upcoming clinical trials. Herein, we review the efficacy and safety of new and emerging biological agents that are currently investigated in IBD clinical trials.
117 citations
TL;DR: The powdered marble was considered as an effective, low cost carbonaceous material to be used for chromium removal from tanning wastewater, removing up to 40% of the treated effluent toxicity than by eggshell 25%.
116 citations
TL;DR: The proposed policy provides more flexibility in maintenance decision-making for complex structure systems, hence leading to significant profits in terms of maintenance cost when compared with existing policies.
116 citations
Authors
Showing all 12161 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Jonathan I. Epstein | 138 | 1121 | 80975 |
| Peter Tugwell | 129 | 948 | 125480 |
| David Brown | 105 | 1257 | 46827 |
| Faiez Zannad | 103 | 839 | 90737 |
| Sabu Thomas | 102 | 1554 | 51366 |
| Francis Martin | 98 | 733 | 43991 |
| João F. Mano | 97 | 822 | 36401 |
| Jonathan A. Epstein | 94 | 299 | 27492 |
| Muhammad Imran | 94 | 3053 | 51728 |
| Laurent Peyrin-Biroulet | 90 | 901 | 34120 |
| Athanase Benetos | 83 | 391 | 31718 |
| Michel Marre | 82 | 444 | 39052 |
| Bruno Rossion | 80 | 337 | 21902 |
| Lyn March | 78 | 367 | 62536 |
| Alan J. M. Baker | 76 | 234 | 26080 |